- Aflibercept, sold
under the
brand names Eylea and
Zaltrap among others, is a
medication used to
treat wet
macular degeneration and
metastatic colorectal...
- " In 2011, Regeneron's
first successful drug was
Eylea for age-related
macular degeneration.
Eylea prevented leaky blood vessels in the eye from causing...
-
autoinflammatory conditions.
Approved by the FDA in
February 2008.[citation needed]
Eylea (aflibercept injection) was
approved by the U.S. Food and Drug Administration...
- May 2024 aflibercept-yszy/Opuviz aflibercept/
Eylea May 2024 aflibercept-jbvf/Yesafili aflibercept/
Eylea May 2024 eculizumab-aeeb/Bkemv eculizumab/Soliris...
-
exifone (INN)
exiproben (INN) Exna
Exosurf Neonatal Exsel Extra-Strength Aim
Extraneal Exxua Exzolt Eylea HD
ezatiostat (USAN, INN)
ezogabine (USAN)...
- In 2019,
identified "key growth"
products were
Xarelto (rivaroxaban),
Eylea (aflibercept),
Stivarga (regorafenib),
Xofigo (radium-223), and Adempas...
-
Healthcare in the
field of
proliferative eye diseases, and
under the name
Eylea it was
approved by the US Food and Drug
Administration (FDA) in 2011; after...
-
occlusion Branch retinal artery occlusion Branch retinal vein
occlusion Eylea Iridodialysis Ischemic optic neuropathy Ophthalmology at a Glance, Jane...
-
edema caused by
diabetes and/or
retinal vein occlusion. On July 29, 2014,
Eylea (aflibercept), an
intravitreal injection produced by
Regeneron Pharmaceuticals...
- Administration.
Archived from the
original on 20
November 2015. "FDA
Approves Eylea for
Macular Degeneration". www.medpagetoday.com. 19
November 2011. Archived...
